HVIVO PLC (HVO) — Interim results for the six months ended 30 June 2026

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the HVIVO Interim Results Investor Presentation. Throughout today's recorded meeting, attendees will be in listen only mode. Questions are encouraged. They can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your question at any time and press send. Before we begin, we'd like to submit the following poll. If you give that your kind attention, I'm sure the company will be most grateful. I'd like to hand over to the management team today. Mo, good afternoon. Thank you, Mark. Good afternoon. Good evening, everyone. Welcome to HVIVO's interim results covering the period of first half of twenty twenty six. This is the obligatory disclaimer we have for obviously, it's the complete under AIM. I'm Yamin Mo Khan. I'm the CEO of HVIVO. I've been here for about four and a half years. On my right here is Steven Pickerton, who's our CFO and has been the CFO for over four years. And on my left, we have our friend Andrew Cashbold, who's our chief scientific officer. And he's been with the company for over twenty years and has really been the the brains behind the development of our challenge models that we see in action these days. So we'll come straight onto the interim results. So for those of you who maybe don't know about the company, we are a full service early stage clinical development provider providing nonclinical and clinical services to both the biotech and pharma industry. We have locations across Europe, in in France, Germany, Netherlands, and also The UK. We have clinical trial units in in London, both in Whitechapel and in Canary Wharf, and three units in Germany in Kiel, Mannheim, and the recently acquired unit in Berlin. In The Netherlands, in both B...